Genetix Group makes fifth bid for Applied Imaging
This article was originally published in Clinica
Genetix Group has raised its offer for Applied Imaging from $23.2m to $25.8m, as it continues to bid against an unnamed third party (see Clinica No 1231, p 14). The UK AIM-listed company has signed four previous merger agreements with San Jose, California-based AI, each of which have been trumped by the other bidder. Its first offer was $18.3m.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.